SyntheticMR develops innovative software solutions for Magnetic Resonance Imaging (MRI) that supports shorter exam times and delivers more information to the clinician. SyntheticMR’s unique technology measures objective MR properties of the patient, rather than just images. Based on these quantitative maps it can deliver adjustable contrast images and fully automatic biomarker segmentation. SyntheticMR’s product SyMRI is sold through partner agreements with GE Healthcare, Siemens Healthineers, Philips Healthcare and Sectra. Please visit

The theory behind the algorithm that will be used in the IMPACT study to detect brain tumors was published in the American Journal of Neuroradiology, “Warntjes et al. Synthesizing a Contrast-Enhancement Map in Patients with High-Grade Gliomas Based on a Postcontrast MR Imaging Quantification Only. AJNR 2018;39:2194-9”. The study showed on 14 patients with high-grade gliomas that a post-GBCA quantification dataset is sufficient to detect Gadolinium-based contrast agent enhancement in brain tumors. This can be helpful to support radiologist to find and characterize the extent of blood-brain barrier damage for malignant tumors. For the entire article see

Example of quantitative MRI on a tumor in the brain. Several quantitative maps are acquired, for example an R1 relaxation rate map (left). The R1 relaxation rate is enhanced when the tumor tissue is infiltrated with a Gadolinium-based contrast agent. The quantitative enhancement is proportional to the GD concentration. Combined with other parameters, qMRI potentially provides a biomarker for tumor detection.